Mineralys Therapeutics Inc

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Mineralys Therapeutics advances in cardio renal disorders amid financial strength

Mineralys Therapeutics is strategically positioned to address aldosterone-driven cardio renal disorders with a strong focus on hypertension and chronic kidney disease.
While the company boasts a robust financial position and progress in clinical trials, challenges such as therapeutic outcomes and regulatory requirements need to be carefully navigated.
Amidst uncertainties and risks, Mineralys Therapeutics has opportunities to expand its product portfolio, explore strategic partnerships, and address unmet medical needs in the cardio renal space.

Mineralys Therapeutics reports positive trial results amidst financial challenges

Mineralys Therapeutics shows promise with positive trial results and a strong cash position, but faces challenges with revised trial timelines and financial losses.
The company's focus on expanding its drug pipeline and governance structure presents opportunities for future growth and market penetration.
Navigating patient enrollment, market potential assessment, and cost management will be crucial for Mineralys to capitalize on its strengths and opportunities.

Mineralys Therapeutics advances hypertension treatment with promising trials and financial insights

Mineralys Therapeutics is making significant progress in developing lorundrostat for hypertension treatment.
Despite challenges in trials and financial pressures, the company remains optimistic and committed to advancing its programs.
Analyst questions and discussions during the earnings call reflect a comprehensive approach to addressing key industry topics.

Mineralys Therapeutics Inc reports Q1 loss, progresses in hypertension trials

Mineralys Therapeutics Inc faces financial challenges with increased expenses but shows strength in clinical trial progress and targeted treatment approaches. Opportunities lie in expanding drug benefits and preventing kidney damage through effective hypertension treatment.

Mineralys Therapeutics progresses key trials amidst financial challenges in Q2

Mineralys Therapeutics is advancing its lead asset lorundrostat for hypertension with key trials progressing as planned.
Financially, the company remains well-capitalized but faces challenges with increased R&D expenses impacting net loss.
Management's confidence in program progress and upcoming milestones signals a positive outlook for the company's future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Late-breaking poster presentation at ASN's Kidney Week 2023  - - - Poster presentation at AHA's Scientific Sessions 2023

Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023

RADNOR, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointments of Daphne Karydas and Glenn Sblendorio to its Board of Directors (the Board). Ms. Karydas and Mr. Sblendorio bring executive, financial and operational leadership experience in biotechnology and biopharmaceuticals markets. In addition, Mineralys announced that Takeshi Takahashi of Catalys Pacific has stepped down from the Board, effective September 12, 2023.

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

RADNOR, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, September 28, 2023 at 9:10 a.m. ET.

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile –

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP), including an enhanced response in individuals with elevated body mass index (BMI) –

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

RADNOR, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced it has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in an oral poster presentation at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10.

Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 199.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?

RADNOR, Pa., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Wells Fargo Securities Healthcare Conference in Boston, Massachusetts on Thursday, September 7, 2023 at 8:45 a.m. ET.

Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023

Mineralys Therapeutics, Inc. (MLYS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Greg Harrison - Bank of America Mohit Bansal - Wells Fargo Rich Law - Credit Suisse Operator Greetings, and welcome to the Mineralys Second Quarter 2023 Earnings Call [Operator Instructions]. As a reminder, this conference is being recorded.

Mineralys Therapeutics, Inc. (MLYS) Q2 2023 Earnings Call Transcript

– Continue enrolling subjects in ongoing pivotal Advance-HTN trial of lorundrostat, for the treatment of patients with uncontrolled or resistant hypertension –

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2023, after the financial markets close on Monday, August 7, 2023.

Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023

Mineralys Therapeutics is investing heavily in R&D for its lead candidate, lorundrostat, a treatment for hypertension and chronic kidney disease. R&D expenses nearly doubled from Q1 2022 to Q1 2023. Despite an increasing net loss, Mineralys' cash and equivalents significantly increased, providing a robust safety net for the company's expansion plans and product development. The company has approximately 6 years of operational runway. Lorundrostat's potential effectiveness and safety in managing chronic kidney disease and hypertension will be evaluated in upcoming clinical trials.

Mineralys Therapeutics: Expanded Phase 2 Trials For Chronic Kidney Disease

– Plan to initiate a Phase 2 proof of concept trial of lorundrostat alone and in combination with an SGLT2 inhibitor for CKD in the second half of 2023 –

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

RADNOR, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will be giving a presentation at the Jefferies Healthcare Conference in New York at 9:30 a.m. ET on Friday, June 9, 2023.

Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference

– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023 –

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

– Topline data from the trial are expected in the first half of 2024 – – A second, pivotal trial of lorundrostat in uncontrolled and resistant hypertension expected to commence enrollment in the second half of 2023 – RADNOR, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the first patient dosed in the ADVANCE-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN) when used as an add-on therapy to standardized background treatment of two or three antihypertensive medications.

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2023, after the financial markets close on Monday, May 15, 2023.

Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023

RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton and Chief Financial Officer and Chief Business Officer Adam Levy will participate in a fireside chat at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 5 p.m. PT

Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023

American Assets

AbbVie

Byline Bancorp

Coastal Financial Corp

Clear Channel Outdoor Holdings

Compass Minerals

Enovix Corporation

Heartland Express

iHeartMedia

JELD-WEN Hld

OPKO Health

PacWest Bancorp

Precigen

Paramount Group

Purple Innovation

B. Riley Financial

Cassava Sciences Inc

Summit Therapeutics

SPDR S&P 500 ETF Trust

Triumph Financial Inc

LendingTree

Vera Therapeutics

Strong Small-Cap Insider Buys: Q1 2023

Mineralys: New IPO And A Leader In The Hypertension Drug Development Space.

Mineralys: New IPO And A Leader In The Hypertension Drug Development Space

– Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 –

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

RADNOR, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter ended December 31, 2022, after the financial markets close on Wednesday, March 15, 2023.

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, announced today that abstracts featuring lorundrostat clinical data from both Phase 2 and Phase 1 studies have been selected for a moderated poster presentation and poster presentation at the American College of Cardiology's 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC), which is scheduled to take place in New Orleans, LA, on March 4-6, 2023.

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

News for Mineralys Therapeutics Inc Stock (MLYS)